Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.16
+0.73005.87%
Post-market: 13.210.0524+0.40%19:56 EDT
Volume:7.07M
Turnover:93.15M
Market Cap:10.50B
PE:-11.77
High:13.53
Open:12.69
Low:12.57
Close:12.43
52wk High:30.05
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.98
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:16.66
PE(LYR):-9.11

Loading ...

Summit Therapeutics Q1 FY26 net loss widens to $189.4 million; operating expenses rise to $195.2 million

Reuters
·
May 01

Summit Therapeutics Q1 adjusted loss narrows despite higher R&D costs

Reuters
·
May 01

Summit Therapeutics Q1 Adjusted EPS USD -0.15 VS. Ibes Estimate USD -0.18

THOMSON REUTERS
·
May 01

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

THOMSON REUTERS
·
May 01

Electric Vehicle Adoption Reaches 'Tipping Point' Globally, Trend Deemed Self-Sustaining

Deep News
·
Apr 26

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Apr 23

Summit partner selection for ASCO plenary signals strong OS, says Leerink

TIPRANKS
·
Apr 22

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

TIPRANKS
·
Apr 22

IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?

Benzinga_recent_news
·
Apr 19

Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Apr 17

Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement

TradingKey
·
Apr 17

Summit Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $45

THOMSON REUTERS
·
Apr 08

Summit Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Apr 08

Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Apr 02

Barclays Remains a Hold on Summit Therapeutics (SMMT)

TIPRANKS
·
Mar 30

Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA

Simply Wall St.
·
Mar 29

Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases

Reuters
·
Mar 28

Summit Therapeutics releases HARMONi Phase 3 ivonescimab HRQoL presentation; trial enrollment totals 438 patients

Reuters
·
Mar 28

Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026

TIPRANKS
·
Mar 27

Summit Therapeutics announces ELCC 2026 presentations; intracranial PFS climbs to 10.1 months on ivonescimab plus chemotherapy in HARMONi patients with baseline brain metastases

Reuters
·
Mar 27